Yttrium Y-90 epratuzumab tetraxetan

DB18801InvestigationalProtein Based Therapies

Yttrium Y-90 epratuzumab tetraxetan: Overview.

Mechanism
Curator reviewed
Code names
2F35K89X9W · 90Y-DOTA-HLL2 · S9S0Y-DOTA-HLL2 · (SUP 90)Y-DOTA-HLL2 · Y-90-DOTA-HLL2

Resolves to

Compound
UNIIJ36232195ECAS501423-25-2
Targets
P20273CD22

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Yttrium Y-90 epratuzumab tetraxetan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In